NIAGEN BIOSCIENCE, INC. (NAGE)

Every figure this model derived for NAGE, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2020-09-30
cash 66,740,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 97,786,000 AssetsCurrent 2026-06-30
current liabilities 15,050,000 LiabilitiesCurrent 2026-06-30
equity 82,528,000 StockholdersEquity 2026-06-30
interest expense 1,000 InterestPaidNet 2025-12-31
ocf 5,949,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 129,084,000 Revenues 2026-06-30
sbc 6,943,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NAGE on one particular measure came for.

RatioValue
cash operating margin14.0
current ratio6.5
current ratio reported6.5
dilution pct9.36
ebit yoy-36.42
fcf margin4.61
growth cv0.44
interest cover10598.0
operating margin8.21
owner earnings margin-0.77
revenue growth10.99
revenue growth per share1.49
roic53.03
rule of 4019.2
sbc pct revenue5.38

What to be careful about

What this model itself distrusts about NAGE's figures. Written by the derivation as it ran, not added afterwards.